176 related articles for article (PubMed ID: 32186164)
21. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
23. Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP).
Moretti A; Gimigliano F; Di Pietro G; Gimigliano R; Iolascon G
Aging Clin Exp Res; 2015 Oct; 27 Suppl 1():S3-9. PubMed ID: 26210371
[TBL] [Abstract][Full Text] [Related]
24. Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study.
Liebich G; Lamy O; Aubry-Rozier B; Gonzalez-Rodriguez E
Bone; 2023 Jul; 172():116764. PubMed ID: 37062514
[TBL] [Abstract][Full Text] [Related]
25. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
26. Fracture risk following intermission of osteoporosis therapy.
Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
[TBL] [Abstract][Full Text] [Related]
27. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Cosman F; Huang S; McDermott M; Cummings SR
J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
[TBL] [Abstract][Full Text] [Related]
28. Prevalent vertebral fractures predict subsequent radiographic vertebral fractures in postmenopausal Korean women receiving antiresorptive agent.
Kim SH; Choi HS; Rhee Y; Kim KJ; Lim SK
Osteoporos Int; 2011 Mar; 22(3):781-7. PubMed ID: 20533028
[TBL] [Abstract][Full Text] [Related]
29. Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia.
Růžičková O; Killinger Z; Kasalický P; Hamilton L; Tyl R; Tomková S; Kalouche-Khalil L
Adv Ther; 2018 Oct; 35(10):1713-1728. PubMed ID: 30191465
[TBL] [Abstract][Full Text] [Related]
30. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
[TBL] [Abstract][Full Text] [Related]
31. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
32. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
33. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.
Silverman S; Viswanathan HN; Yang YC; Wang A; Boonen S; Ragi-Eis S; Fardellone P; Gilchrist N; Lips P; Nevitt M; Palacios Gil-Antuñano S; Pavelka K; Revicki D; Simon J; Macarios D; Siris ES
Osteoporos Int; 2012 Apr; 23(4):1361-9. PubMed ID: 21769664
[TBL] [Abstract][Full Text] [Related]
34. Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors.
Antonini S; Pedersini R; Birtolo MF; Baruch NL; Carrone F; Jaafar S; Ciafardini A; Cosentini D; Laganà M; Torrisi R; Farina D; Leonardi L; Balzarini L; Vena W; Bossi AC; Zambelli A; Lania AG; Berruti A; Mazziotti G
J Endocrinol Invest; 2024 Feb; 47(2):433-442. PubMed ID: 37592052
[TBL] [Abstract][Full Text] [Related]
35. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
36. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
37. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
38. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
[TBL] [Abstract][Full Text] [Related]
39. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
[TBL] [Abstract][Full Text] [Related]
40. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
